Valentina Natoli

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Journal: Expert opinion on biological therapy

Published: June 23, 2026

The private truncating Toll-like receptor 7 p.Glu834* variant associates with juvenile-onset systemic lupus erythematosus and pathological cytokine expression in vitro.

The private truncating Toll-like receptor 7 p.Glu834* variant associates with juvenile-onset systemic lupus erythematosus and pathological cytokine expression in vitro.

Journal: Annals of the rheumatic diseases

Published: March 20, 2026

Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.

Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.

Journal: Current rheumatology reports

Published: October 09, 2025

Discordance between non-zero physician's global scores and absence of active joints in juvenile idiopathic arthritis: multicenter vs. single-center cohorts.

Discordance between non-zero physician's global scores and absence of active joints in juvenile idiopathic arthritis: multicenter vs. single-center cohorts.

Journal: Frontiers in pediatrics

Published: September 10, 2025

Redox imbalance and NLRP3 activation: H syndrome mistaken for CAPS-a case report.

Redox imbalance and NLRP3 activation: H syndrome mistaken for CAPS-a case report.

Journal: Rheumatology (Oxford, England)

Published: August 08, 2025

Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review.

Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review.

Journal: Biologics : targets & therapy

Published: May 08, 2025

Toward a Treat-to-Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement?

Toward a Treat-to-Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement?

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: April 25, 2025

Forecasting Achievement of Inactive Disease in Juvenile Idiopathic Arthritis with Artificial Intelligence.

Forecasting Achievement of Inactive Disease in Juvenile Idiopathic Arthritis with Artificial Intelligence.

Journal: Children (Basel, Switzerland)

Published: April 25, 2025

Common Toll-like receptor 7 variants define disease risk and phenotypes in juvenile-onset systemic lupus erythematosus.

Common Toll-like receptor 7 variants define disease risk and phenotypes in juvenile-onset systemic lupus erythematosus.

Journal: Journal of autoimmunity

Published: April 22, 2025

Genetic variability associates with ancestry, age at disease onset, organ involvement and disease severity in juvenile-onset systemic lupus erythematosus.

Genetic variability associates with ancestry, age at disease onset, organ involvement and disease severity in juvenile-onset systemic lupus erythematosus.

Journal: Clinical immunology (Orlando, Fla.)

Published: March 27, 2025

Efficacy of High-Dose Intravenous Anakinra in Pediatric TAFRO Syndrome: Report of Two Cases and Literature Review.

Efficacy of High-Dose Intravenous Anakinra in Pediatric TAFRO Syndrome: Report of Two Cases and Literature Review.

Journal: Pediatric blood & cancer

Published: January 30, 2025

Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis.

Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis.

Journal: Frontiers in immunology

Published: November 10, 2024

Showing 1-12 of 33

Last Updated: 09/26/2026